Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage gene editing company that regularly issues news and updates about its in vivo CRISPR-based pipeline. Company announcements emphasize the development of transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 systems, proprietary targeted lipid nanoparticle delivery, and a differentiated gene upregulation strategy applied to serious diseases.
News about Editas Medicine frequently covers progress with its lead in vivo development candidate, EDIT-401, an LDLR-targeted gene editing medicine designed to treat hyperlipidemia by increasing LDL receptor expression and reducing LDL cholesterol (LDL-C) levels. Recent releases have described preclinical proof-of-concept data in non-human primates and mice, showing approximately 90% or greater reductions in LDL-C after a single dose, as well as presentations at major scientific meetings such as the European Society of Gene and Cell Therapy Congress and the American Heart Association Scientific Sessions.
Investors and followers of EDIT can also expect updates on Editas’ in vivo hematopoietic stem cell program for sickle cell disease and beta thalassemia, including data on HBG1/2 promoter editing, fetal hemoglobin upregulation, and targeted lipid nanoparticle delivery in humanized mice and non-human primates. Additional news items highlight in vivo proof-of-concept for undisclosed liver targets, conference presentations at ASGCT, EHA, and TIDES, and participation in healthcare and investor conferences.
Financial news from Editas Medicine includes quarterly results, collaboration milestones such as the CD19 HD allogeneic CAR T program with Bristol Myers Squibb, and updates on cash runway supported by cash, marketable securities, at-the-market equity proceeds, and payments under its license agreement with Vertex Pharmaceuticals. This news page helps readers follow how scientific data, regulatory plans, collaborations, and financial developments shape the EDIT investment story over time.
Editas Medicine provides updates on its ocular and blood disease programs, highlighting progress in its clinical trials. The company plans to accelerate enrollment in the Phase 1/2 BRILLIANCE trial for EDIT-101 and is set to dose the first patient in the adult mid-dose cohort within Q1 2021. EDIT-301 will begin dosing for sickle cell disease patients in 2021, with an IND filing for beta-thalassemia expected by year-end. Future goals include declaring a candidate for autosomal dominant retinitis pigmentosa and advancing solid tumor treatments.
Editas Medicine has announced FDA clearance to begin the safety phase of its EDIT-301 clinical trial for sickle cell disease, marking a significant milestone for the company and potential patients. EDIT-301, an experimental gene editing therapy, is developed using CRISPR/Cas12a technology and aims to address the unmet medical needs of those suffering from this inherited disorder. The company is preparing to initiate the RUBY trial, which will assess both the safety and efficacy of EDIT-301. An improved potency assay will be required before moving to the efficacy phase.
Editas Medicine (Nasdaq: EDIT) announced the resignation of Chief Scientific Officer Charles Albright, effective January 15, 2021. A search for his successor is currently in progress. Albright has been pivotal in advancing Editas's genomic medicine initiatives and CRISPR gene editing programs. The company focuses on developing transformative genomic medicines aimed at serious diseases worldwide. While the transition may pose challenges, Editas continues its commitment to innovation in the field of genome editing.
Editas Medicine (Nasdaq: EDIT) announced it will present an overview at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. The event will be held virtually, and a live webcast will be accessible on Editas Medicine's website, with an archived replay available for 30 days post-presentation. As a leader in genome editing, Editas focuses on CRISPR technologies to develop precision genomic medicines for serious diseases globally.
Editas Medicine (NASDAQ: EDIT) has appointed Meeta Chatterjee, Ph.D., to its Board of Directors. Dr. Chatterjee brings over 30 years of experience in biopharmaceuticals, focusing on research, development, mergers, and acquisitions. She currently serves as Senior VP of Global Business Development at Legend Biotech. Her previous role at Merck involved overseeing critical business development transactions. This strategic addition aims to enhance Editas’ leadership and bolster its goal of advancing CRISPR technology for treating serious diseases.
Editas Medicine (Nasdaq: EDIT) announced the submission of an IND application to the FDA for a Phase 1/2 trial of EDIT-301, a CRISPR-based treatment for sickle cell disease. This marks a significant milestone in their development of ex vivo cell therapies. EDIT-301 aims to increase fetal hemoglobin levels to offer a durable treatment solution. The company has appointed a lead principal investigator and engaged a CRO, with clinical trial materials already being manufactured. This submission highlights Editas' commitment to providing transformative therapies for those affected by sickle cell disease.
Editas Medicine announced promising preclinical data for EDIT-301, an innovative autologous cell therapy targeting sickle cell disease and beta-thalassemia. Utilizing CRISPR/Cas12a technology, the therapy demonstrated high gene editing efficiency and significant fetal hemoglobin induction in clinical studies. The company successfully developed a scalable manufacturing process, showing consistent, robust results in animal models. Editas plans to file an IND for EDIT-301 by the end of 2020, aiming to enter a Phase 1/2 clinical trial, potentially offering a transformative solution for patients.
Editas Medicine (Nasdaq: EDIT) has granted inducement awards to Lisa Michaels, M.D., the newly appointed Executive Vice President and Chief Medical Officer. The Board approved a stock option grant for up to 120,000 shares at $30.41 per share, which vests over four years. Additionally, Dr. Michaels received a restricted stock unit award for 20,000 shares, vesting at 25% annually over four years. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are contingent on her continued employment with Editas Medicine.
Editas Medicine, a prominent genome editing company, announced its participation in the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020, at 10:15 AM ET. The presentation will be webcast live on their website, with archived recordings available for 30 days post-event.
Editas focuses on utilizing CRISPR technologies to develop precise genomic medicines aimed at treating serious diseases globally.
Editas Medicine has appointed Lisa A. Michaels, M.D. as its new Executive Vice President and Chief Medical Officer. Dr. Michaels brings over 25 years of experience in clinical research and drug development from her previous role at Bayer Pharmaceuticals. She will oversee clinical research and drug development for Editas' pipeline, notably focusing on EDIT-301 for sickle cell disease. The company recently reacquired rights to its ocular pipeline, enhancing its position in the genome editing landscape.